GUGGENHIME ANDREW 4

4 · Vaxcyte, Inc. · Filed Mar 2, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

Vaxcyte (PCVX) President/CFO Andrew Guggenhime Receives Awards, Surrenders Shares

What Happened

Andrew Guggenhime, President and CFO of Vaxcyte (PCVX), received equity awards on February 26, 2026: 44,864 RSU-type awards and 74,993 derivative awards (total 119,857 units) granted at $0.00 per share.
To cover tax withholding obligations on vesting, Guggenhime surrendered 898 shares on February 28, 2026 and 1,009 shares on March 2, 2026 at $61.98 per share (proceeds/withholding value $55,658 and $62,538, respectively; total $118,196).
These transactions were awards and routine tax-withholding share surrenders — not open-market sales.

Key Details

Transaction dates and prices:
- 2026-02-26: Award of 44,864 shares (RSU) and 74,993 derivative units @ $0.00.
- 2026-02-28: 898 shares surrendered for tax withholding @ $61.98 (value $55,658).
- 2026-03-02: 1,009 shares surrendered for tax withholding @ $61.98 (value $62,538).
Shares surrendered total: 1,907; withholding value total: $118,196.
Shares owned after the reported transactions: not specified in the provided filing.
Notable footnotes:
- F1: The RSUs represent contingent rights to one share each; vesting: 1/4 on Sept 7, 2026, then 1/8 every six months thereafter (service-based).
- F2: The 898 and 1,009-share disposals are shares surrendered to cover tax withholding upon RSU vesting (cashless withholding).
- F3: Some shares are held by ALG 2025 GRAT HOLDINGS LLC (a trust entity connected to the reporting person).
- F4: The 74,993 derivative units vest 1/48 on March 26, 2026 and monthly thereafter (service-based option-style schedule).
Filing timeliness: Report filed 2026-03-02 for transactions through 2026-02-26 — appears timely (within the Form 4 two-business-day window).

Context

These were compensation awards and routine tax-withholding actions, not market sales or purchases; share-withholding to satisfy taxes is common and does not necessarily indicate insider sentiment.
The derivative award follows a monthly vesting schedule (1/48 starting 3/26/2026); RSUs have a later graded vesting schedule (first quarter vests 9/7/2026).

Form 4

Period: 2026-02-26

PRESIDENT AND CFO

Transactions

Award
Common Stock
[F1]
2026-02-26+44,864→ 107,323 total
Tax Payment
Common Stock
[F2]
2026-02-28$61.98/sh−898$55,658→ 106,425 total
Tax Payment
Common Stock
[F2]
2026-03-02$61.98/sh−1,009$62,538→ 105,416 total
Award
Stock Option (right to buy)
[F4]
2026-02-26+74,993→ 74,993 total
Exercise: $60.00Exp: 2036-02-26→ Common Stock (74,993 underlying)

Holdings

Footnotes (4)

[F1]Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
[F2]Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
[F3]Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
[F4]1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Signature

Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact|2026-03-02

1 file